Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marban - Co-Founder, President, CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co. Operator Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics, Inc. First Quarter 2022 Financial Earnings Call. [Operator Instructions]. At this time, I would like to turn the call over to Mr. Bergmann, C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marban - Chief Executive Officer Conference Call Participants Emanuela Branchetti - H.C. Wainwright Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-as ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Greetings, and welcome to the Capricor Therapeutics Third Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operator Instructions] ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or ot ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Emanuela Branchetti - H.C. Wainwright Alan Leong - BioWatch News Operator Ladies and gentlemen, good day and welcome to the Capricor Therapeutics Inc. Second Quarter 2021 Earnings Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to A ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or o ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Alan Leong - BioWatch News Operator Greetings. And welcome to Capricor Therapeutics First Quarter 2021 Earnings and Corporate Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions ...

Financial Performance - Grant income for the years ended December 31, 2020 and 2019 was approximately $0.2 million and $0.5 million, respectively, indicating a decrease of approximately 60% in 2020 compared to 2019[535]. - General and Administrative (G&A) expenses for the years ended December 31, 2020 and 2019 were approximately $5.5 million and $3.6 million, respectively, reflecting an increase of approximately 52.8% in 2020[537]. - The increase in G&A expenses in 2020 was primarily due to a $1.2 million increase in stock-based compensation expense and a $0.5 million increase in salaries and recruiting related expenses[537]. - Investment income decreased from $94,791 in 2019 to $32,943 in 2020, a decline of approximately 65.3% due to reduced interest rates[540]. - The company reported a net loss of approximately $13.7 million for the year ended December 31, 2020, compared to a net loss of $10.4 million in 2019[548]. - Cash used in operating activities rose to approximately $10.1 million in 2020 from $6.8 million in 2019, an increase of about 48.5%[548]. - The company raised approximately $33.0 million from the sale of common stock in 2020, compared to $9.2 million in 2019, marking an increase of about 258.7%[550]. Research and Development - Research and Development (R&D) expenses increased from approximately $5.1 million in 2019 to $8.5 million in 2020, a rise of about 66.7%[539]. - R&D expenses primarily include salaries, clinical trial costs, and manufacturing costs, with expenses recognized as incurred[583]. - The accrual policy for R&D activities aims to match expenses with actual services received, with variations in payment flows due to contract negotiations[585]. - The company monitors activity levels through communication with CROs and vendors, ensuring expenses align with budgeted amounts[584]. - The clinical trial accrual process is designed to reflect appropriate expenses in financial statements based on the progress of trials[592]. Clinical Trials and Product Development - The company has completed the Phase II clinical trial (HOPE-2) for CAP-1002, showing improvements in multiple measures of upper limb, cardiac, and respiratory functions[507]. - The FDA has encouraged the company to conduct a Phase III study for CAP-1002, although discussions regarding the pathway forward are still ongoing[507]. - The INSPIRE trial for CAP-1002 in severe or critical COVID-19 patients is a Phase II, randomized, double-blind, placebo-controlled study enrolling up to 60 patients[509]. - The company is developing two vaccine candidates for COVID-19, including a tripartite exosome-mRNA vaccine, with plans to file an IND by the third quarter of 2021[510]. - The company has submitted an IND for CAP-2003 to investigate its use in patients with Duchenne Muscular Dystrophy (DMD) and is evaluating the next steps for this program[514]. Funding and Grants - The Company received a CIRM Grant Award of approximately $3.4 million for its Phase I/II clinical trial, requiring a co-funding of about $2.3 million from the Company[565]. - As of December 31, 2020, the liability balance for the CIRM Award was approximately $3.4 million, with all milestones completed by June 2019[567]. - The NIH grant for CAP-2003 amounted to approximately $4.2 million, with $0.7 million incurred by June 30, 2019, and the award was closed in Q2 2019[568]. - The Department of Defense grant totaled approximately $2.4 million, with about $2.3 million utilized, and a no-cost extension granted until September 29, 2020[569]. Cash and Investments - Cash, cash equivalents, and marketable securities increased from approximately $9.9 million in 2019 to $32.7 million in 2020, a growth of about 230.5%[544][550]. - The net increase in cash and cash equivalents for 2020 was approximately $28.8 million, compared to a decrease of $646,000 in 2019[547]. - The fair value of cash and cash equivalents as of December 31, 2020, was approximately $32.7 million[598]. - The investment portfolio primarily consists of money market funds and short-term U.S. treasuries, aiming to limit credit exposure and default risk[598]. - The company does not hedge interest rate exposure and believes that a hypothetical 100 basis point change in interest rates would not significantly impact the fair value of its investment portfolio[599]. Stock-Based Compensation - Stock-based compensation expense is recognized over the vesting period, with significant future non-cash compensation expenses expected[591]. - The company accounts for stock options using the Black-Scholes option-pricing model, requiring assumptions about various variables[589].